Deng X, He H Q, Zhou Y, Yan R, Tang X W, Zhu Y, Xu X P, Lyu H K
Department of Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, China.
Zhonghua Yu Fang Yi Xue Za Zhi. 2022 May 6;56(5):554-560. doi: 10.3760/cma.j.cn112150-20211110-01044.
Japanese encephalitis (JE) virus is the leading cause of vaccine-preventable encephalitis in Asia and the Western Pacific, which mainly invades central nervous system. Vaccination is the most important strategy to prevent JE. Currently, both live attenuated Japanese encephalitis vaccines (JE-L) and inactivated vaccines (JE-I) are in use. Due to the supply of vaccines and the personal choice of recipients, there will be a demand for interchangeable immunization of these two vaccines. However, relevant research is limited. By reviewing domestic and foreign research evidence, this article summarizes the current situation of the interchangeable use of JE-L and JE-I, and makes recommendations when the interchangeable immunization is in urgent need, so as to provide reference for practical vaccination and policymaking in China.
日本脑炎（JE）病毒是亚洲和西太平洋地区疫苗可预防脑炎的主要病因，主要侵袭中枢神经系统。接种疫苗是预防日本脑炎的最重要策略。目前，减毒活日本脑炎疫苗（JE-L）和灭活疫苗（JE-I）均在使用。由于疫苗供应和受种者个人选择等因素，这两种疫苗存在交替接种的需求。然而，相关研究有限。通过回顾国内外研究证据，本文总结了JE-L和JE-I交替使用的现状，并在急需交替接种时提出建议，为我国实际疫苗接种和政策制定提供参考。
